MGMT and central nervous system cancer: In clinical practice, the methylation status of the MGMT promoter has been affirmed as a prognostic indicator, pivotal in forecasting the sensitivity of patients with glioma to temozolomide, as well as predicting their subsequent clinical outcomes (Melguizo et al., 2012; Mansouri et al., 2019).